RT Journal Article
SR Electronic
T1 Role of IL-23 neutralization in psoriasis – insights from a mechanistic PK/PD model and meta-analysis of clinical data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.07.21253086
DO 10.1101/2021.03.07.21253086
A1 Georgi I. Kapitanov
YR 2021
UL http://medrxiv.org/content/early/2021/03/09/2021.03.07.21253086.abstract
AB Blocking of IL-23 has shown a profound effect on patient outcomes in psoriasis. The current IL-23 binding monoclonal antibodies show differences in dosing regimens, pharmacokinetics, affinity for the target, and efficacy outcomes in the clinic. The goal of the current work is to use a mechanistic pharmacokinetics/pharmacodynamics mathematical model to estimate projected free IL-23 neutralization for the different therapeutic molecules and connect it to clinical efficacy outcomes. The meta-analysis indicates a sigmoid-like relationship and suggests that the best current anti-IL23 antibodies are close to saturating the efficacy that can be achieved by this pathway in psoriasis.Competing Interest StatementThe author is an employee of Pfizer, Inc. The author declares no other competing interests for this work.Funding StatementNo external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The manuscript does not require oversight or approvals - all data is available in the literature.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available in the literature and is referenced within the manuscript.